Merck KGaA Entered into a Collaboration with Hengrui to Strengthen its Oncology Pipeline for Next-Generation Selective PARP1 Inhibitor and Antibody Drug Conjugate

Driven by the Growing Demand for Biologics, the Biopharmaceutical Contract Manufacturing Market is Expected to Grow at an Annualized Rate of 8.1%..

A new analysis by Roots Analysis has predicted that the antibody drug conjugates (ADC) market will be worth more than $15 billion by 2030, growing at a compound annual growth rate (CAGR) of over 20 percent due to their growing popularity and therapeu..

For kidneys, Roots Analysis, a medical-technology consultancy, reckons that should be possible in about six years’ time. Livers, which have a natural tendency to regenerate anyway, should also arrive reasonably soon. Hearts, with their complex inte..

Roots Analysis predicts the gene therapy market as a whole to reach ~$11 bln by 2025..

Roots Analysis, a market research and consulting firm for the pharmaceutical industry, says that growth will add to the estimated “current global contract pharmaceutical installed manufacturing capacity of 125 million liters [30.4 million U.S. gall..

There are few companies with the capability to commercially manufacture viral vectors; most of the 24 firms identified by Roots Analysis in a 2016 report are CDMOs...

Roots Analysis estimates there are over 500 gene therapy candidates in clinical development, with approximately 1,700 clinical studies underway around the world...